Tag

Daraxonrasib

All articles tagged with #daraxonrasib

health8 days ago•4 min saved

Early Detection and New RAS Inhibitors Aim to Triple Pancreatic Cancer Survival

Researchers are pursuing a strategy of 'cancer interception' to treat pre-cancerous pancreatic tissue before it becomes malignant, aiming to boost five-year survival from 13.7% to 50%. This approach leverages the recent FDA approval of daraxonrasib, a drug that nearly doubled median survival in metastatic cases. While current trials focus on advanced disease, new studies are testing the drug for early-stage prevention and screening.

via nature.com|

#cancer-interception #daraxonrasib #early-detection

health10 days ago•3 min saved

FDA Approves First RAS Inhibitor, Doubling Survival for Pancreatic Cancer Patients

The FDA has approved daraxonrasib (Rasonque), the first drug in its class to target RAS mutations, a breakthrough for pancreatic cancer. In a trial of 500 patients, the drug doubled median survival to 13.2 months compared to 6.7 months for chemotherapy. Developed by Revolution Medicines, the drug addresses a target previously deemed untargetable, offering new hope for a disease with a 13% five-year survival rate.

via Gizmodo|

#daraxonrasib #fda-approval #health

health1 month ago•2 min saved

Daraxonrasib Extends Survival in Pancreatic Cancer Trial

In an expanded-access trial of the FDA-approved pancreatic cancer drug daraxonrasib, patients showed median survival roughly doubling from 6.7 to 13.2 months and tumor shrinkage, with a South Portland man reporting improved quality of life.

via Portland Press Herald - Maine Sunday Telegram|

#cancer-treatment #daraxonrasib #expanded-access

health1 month ago•4 min saved

Pancreatic cancer drug shows early promise against lung cancer

A small trial of daraxonrasib (Rasonque) in non-small-cell lung cancer with RAS mutations showed tumor shrinkage in more than 30% of participants, signaling potential beyond pancreatic cancer. A larger randomized trial is under way to confirm efficacy and durability, with regulatory decisions pending. The drug, which had already received FDA approval for pancreatic cancer after earlier successes, works as a molecular glue that exposes RAS to inhibition via cyclophilin A, a mechanism that could extend to other hard-to-treat tumors, though resistance can emerge.

via Nature|

#clinical-trial #daraxonrasib #health

health1 month ago•23 min saved

Charleston Gains Access to Breakthrough KRAS Pancreatic Cancer Drug

Charleston-area patients with metastatic pancreatic cancer are receiving daraxonrasib, a KRAS-targeted drug that showed in Phase 3 trials to roughly double median survival (about 13.2 months versus 6.6 with chemotherapy) via an expanded-access program before FDA approval. Terri Truere became the first local patient treated at Roper St. Francis Cancer Center, a development clinicians say could improve targeting of the KRAS mutation and potentially expand surgical options, though the drug carries notable side effects such as mouth sores, sore throat and rash. The rollout offers optimism for pancreatic cancer treatment and for next-generation KRAS therapies.

via Post and Courier|

#charleston #daraxonrasib #expanded-access

health1 month ago•59 min saved

KRAS-targeting pancreatic cancer drug boosts survival, reaches Charleston patients

A Phase 3 trial showed daraxonrasib, a KRAS-targeting therapy for metastatic pancreatic cancer, nearly doubles median survival (about 13.2 months vs 6.6) and is moving into expanded-access programs, with Terri Truere in Charleston among the first patients in the area to receive it ahead of FDA approval. The drug is not yet approved, but more SC sites are preparing to offer it; it carries notable side effects such as mouth sores and rash, and access remains limited. Doctors see promise that KRAS targeting could improve outcomes and potentially expand surgical eligibility in some patients.

via Yahoo|

#charleston #daraxonrasib #expanded-access

health1 month ago•0 min saved

Investigational pancreatic cancer pill may double survival, early data suggest

An investigational drug called daraxonrasib given to a pancreatic cancer patient at Massachusetts General Hospital is described as a potential breakthrough, with early results indicating that survival could be doubled. The report frames this as a historic advance after decades of research, though access to full details currently requires login or subscription to the Globe.

via The Boston Globe|

#cancer-treatment #clinical-trial #daraxonrasib

health1 month ago•3 min saved

KRAS-targeting drug offers renewed hope in advanced pancreatic cancer

An experimental KRAS-inhibiting pill, daraxonrasib, significantly extends median survival in advanced pancreatic cancer (13.2 months vs. 6.7 months with chemotherapy) in a phase 3 trial, and is available to eligible patients via the FDA Expanded Access Protocol at 10 Intermountain Health hospitals while full approval is pending; it’s a second-line option with manageable side effects and is not a cure.

via USA Today|

#daraxonrasib #expanded-access-protocol #health

health1 month ago•17 min saved

Promising KRAS-targeting drug daraxonrasib doubles survival in late-stage pancreatic cancer

Daraxonrasib, a KRAS-targeting drug for stage 4 pancreatic cancer, doubled survival in trials (6.7 to 13.2 months) and is being provided through an Extended Access Program ahead of FDA approval; nine Intermountain Health patients are enrolled. It is not a cure and carries side effects like rash, diarrhea, and mouth sores.

via ksl.com|

#daraxonrasib #extended-access-program #fda-approval

health2 months ago•3 min saved

Daraxonrasib Goes to Patients Early Through Expanded Access Ahead of FDA Decision

Following dramatic RASolute 302 results, physicians nationwide are offering the oral RAS inhibitor daraxonrasib to patients under expanded-access programs before FDA approval. The drug nearly doubled median overall survival in previously treated metastatic pancreatic cancer (6.7 to 13.2 months) and Revolution Medicines has filed for FDA approval. More than 2,000 patients are on EAP, with sites across the U.S.; institutions cover IRB and safety monitoring costs. Huntsman Cancer Institute reported about 50 patients through its EAP; setup takes 2–3 weeks and delivery occurs in about 7–10 days after consent. Side effects include skin toxicity, managed with dermatology input and topical/doxycycline. Trials continue in first-line metastatic pancreatic cancer, post-surgery settings, and second-line RAS-mutant NSCLC.

via Medscape|

#daraxonrasib #expanded-access-program #fda-approval

health2 months ago•7 min saved

Illinois patients begin expanded-access rollout of experimental pancreatic cancer drug

Illinois and other states are starting to treat metastatic pancreatic cancer patients with the experimental drug daraxonrasib under an FDA-expanded access program ahead of full FDA approval; early clinical data show a median survival of about 13 months with daraxonrasib versus about six months with additional chemotherapy, with doctors calling it a potential game changer. The drug is provided at no cost through Revolution Medicines, and physicians submit requests for each patient as several Illinois hospitals begin offering it.

via chicagotribune.com|

#city-of-hope-chicago #clinical-trial #daraxonrasib

biotech2 months ago•2 min saved

Pancreatic cancer braces for post-daraxonrasib era

At a European pancreatic cancer conference, experts hailed the anticipated launch of daraxonrasib as a potential milestone that could reshape care, echoing the impact of checkpoint inhibitors. But they warned the new therapy would bring opportunities and challenges—from access and pricing to real-world effectiveness and how it will be integrated into standard treatment and combination strategies as data emerge.

via STAT|

#biotech #clinical-trials #daraxonrasib

health3 months ago•21 min saved

Pancreatic cancer breakthrough prompts shift toward early-detection era

A new pancreatic cancer drug, daraxonrasib, has shown the ability to double median survival in advanced cases versus chemotherapy, fueling optimism about treating the disease earlier. At UC San Diego’s Moores Cancer Center, researchers note that early intervention could maximize benefits as part of PRECEDE, a global program screening at‑risk individuals with regular blood tests and imaging across 65 centers, with about 12,000 of 20,000 enrolled and roughly 75% of detected cases currently found at stage I. AI in imaging is anticipated to boost early detection, while the FDA has granted expanded access to the drug for patients not eligible for trials. Experts envision “interception studies” that could use RAS inhibitors earlier to prevent spread, potentially combining resection with targeted therapy for even better outcomes.

via San Diego Union-Tribune|

#daraxonrasib #early-detection #health

biotech3 months ago•3 min saved

KRAS combo data prompts Revolution Medicines toward Phase 3

Revolution Medicines revealed early data for a two-KRAS inhibitor drug combination, including Daraxonrasib, and plans a Phase 3 trial, signaling potential progress in targeting KRAS-driven cancers.

via Endpoints News|

#biotech #daraxonrasib #esmo

health4 months ago•3 min saved

RAS-targeting drug daraxonrasib nearly doubles median survival in pancreatic cancer trial

A phase 3 trial published in the New England Journal of Medicine finds the oral RAS-inhibitor daraxonrasib significantly improves survival for metastatic pancreatic cancer, with a median of 13.2 months versus 6.7 months with chemotherapy; the FDA has granted an early-access program ahead of potential approval later in 2026, marking a potential paradigm shift by directly targeting mutant RAS to halt cancer growth.

via USA Today|

#daraxonrasib #health #pancreatic-cancer